- Home
- SIGA vs RNA Comparison
SIGA vs RNA Comparison
Compare SIGA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | RNA |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 222.5M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SIGA | RNA |
|---|---|---|
| Price | $3.06 | $13.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | ★ 607.7K | 127.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $224.81 | $18.11 |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $11.13 |
| 52 Week High | $9.45 | $73.06 |
Technical Indicators
Market Signals| Indicator | SIGA | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 63.95 |
| Support Level | $3.01 | $12.72 |
| Resistance Level | $4.84 | $14.05 |
| Average True Range (ATR) | 0.13 | 0.51 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 68.97 | 86.89 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.